Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Industry: Healthcare

OFF LIST - 1699 consecutive market days: OFF LIST as of 09/04/2009 Through 11/14/2016

Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, a preclinical ALK inhibitor. The company was founded in 2013 and is headquartered in San Diego, California.

Current Quote*
Last: $68.350
Change: 1.360
Book: $6.005
Volume: 121,097

As Of: 05/28 12:46 ET
*Quotes delayed by 20min.

Graphs for TPTX


3 Month Graph


6 Month Graph


1 Year Graph